At 12 months, 5.8% of patients did not meet the ELN2013 milestones of ≤0.1% BCR::ABL1IS, considered a “safe haven” for CML patients [16]. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.